STOCK TITAN

ALT5 Sigma Corporation (ALTS) 10-K Filings

ALTS NASDAQ

Ticker history: ALTS became AIFC (AI Financial Corporation) on . Earlier news and filings retain their original names and dates. View ALTS history.

Here are the 10-K annual reports from ALT5 Sigma Corporation (ALTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow ALTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALTS filings page.

Rhea-AI Summary

ALT5 Sigma Corporation filed Amendment No. 1 to its annual report dated December 27, 2025 to add its Compensation Recoupment (Clawback) Policy as Exhibit 97.1. The company states that, other than including this replacement exhibit and updating the amendment date, no changes were made to the original annual report.

The filing also notes that the aggregate market value of common stock held by non-affiliates was approximately $160.6 million based on the closing price on June 27, 2025, and that 127,166,254 shares of common stock were outstanding as of April 9, 2026.

Rhea-AI Summary

ALT5 Sigma Corporation (ALTS) describes its transformation into a fintech and digital-asset platform, centered on the ALT5 Prime trading platform, ALT5 Pay crypto payments gateway, and StrataCarte multi-currency card program. The company serves roughly 1,900 corporate customers in 50 countries, targeting banks, broker-dealers, funds, and merchants.

ALT5 Sigma Canada’s cumulative transaction volume reached $8.0 billion, rising from $39.0 million in 2020 to $3.5 billion in 2025. Revenue progressed from $3.5 million in 2021 to $23.5 million in 2025, with profitability fluctuating between small profits and net losses.

The company completed key acquisitions, including ALT5 Sigma, Inc. in 2024 and Fortress II Holdings Ltd. (Mswipe/StrataCarte) in 2025, expanding payments and card capabilities. It also retains a discontinued biotechnology segment, Alyea Therapeutics, and is exploring a formal separation.

Management discloses material weaknesses in internal control over financial reporting, including IT control gaps, weak contract-to-invoice processes, and insufficient assessment of significant transactions. The filing details extensive risks from crypto market volatility, regulation, custody and cybersecurity threats, banking relationships, and evolving tax and sanctions regimes.